Edwards Lifesciences Competitors

Abbott Laboratories (NYSE:ABT) and Edwards Lifesciences (NYSE:EW) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, profitability, valuation and risk.

Risk & Volatility

Abbott Laboratories has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500.

Earnings and Valuation

This table compares Abbott Laboratories and Edwards Lifesciences' revenue, earnings per share and valuation.

Abbott Laboratories has higher revenue and earnings than Edwards Lifesciences. Abbott Laboratories is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Abbott Laboratories and Edwards Lifesciences' net margins, return on equity and return on assets.

Institutional & Insider Ownership

72.6% of Abbott Laboratories shares are held by institutional investors. Comparatively, 80.9% of Edwards Lifesciences shares are held by institutional investors. 1.7% of Abbott Laboratories shares are held by company insiders. Comparatively, 1.5% of Edwards Lifesciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and price targets for Abbott Laboratories and Edwards Lifesciences, as reported by MarketBeat.

Abbott Laboratories currently has a consensus price target of $115.6875, indicating a potential upside of 3.05%. Edwards Lifesciences has a consensus price target of $90.8704, indicating a potential upside of 3.99%. Given Edwards Lifesciences' higher possible upside, analysts clearly believe Edwards Lifesciences is more favorable than Abbott Laboratories.

Summary

Edwards Lifesciences beats Abbott Laboratories on 8 of the 14 factors compared between the two stocks.

Medtronic (NYSE:MDT) and Edwards Lifesciences (NYSE:EW) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, profitability, valuation and risk.

Institutional & Insider Ownership

79.2% of Medtronic shares are held by institutional investors. Comparatively, 80.9% of Edwards Lifesciences shares are held by institutional investors. 0.5% of Medtronic shares are held by company insiders. Comparatively, 1.5% of Edwards Lifesciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and price targets for Medtronic and Edwards Lifesciences, as reported by MarketBeat.

Medtronic currently has a consensus price target of $122.2963, indicating a potential upside of 4.14%. Edwards Lifesciences has a consensus price target of $90.8704, indicating a potential upside of 3.99%. Given Medtronic's stronger consensus rating and higher possible upside, analysts clearly believe Medtronic is more favorable than Edwards Lifesciences.

Earnings and Valuation

This table compares Medtronic and Edwards Lifesciences' revenue, earnings per share and valuation.

Medtronic has higher revenue and earnings than Edwards Lifesciences. Medtronic is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Medtronic and Edwards Lifesciences' net margins, return on equity and return on assets.

Risk & Volatility

Medtronic has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500.

Summary

Edwards Lifesciences beats Medtronic on 8 of the 15 factors compared between the two stocks.

Edwards Lifesciences (NYSE:EW) and Intuitive Surgical (NASDAQ:ISRG) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, dividends, valuation and analyst recommendations.

Institutional and Insider Ownership

80.9% of Edwards Lifesciences shares are held by institutional investors. Comparatively, 86.5% of Intuitive Surgical shares are held by institutional investors. 1.5% of Edwards Lifesciences shares are held by company insiders. Comparatively, 1.6% of Intuitive Surgical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and recommmendations for Edwards Lifesciences and Intuitive Surgical, as reported by MarketBeat.

Edwards Lifesciences presently has a consensus price target of $90.8704, indicating a potential upside of 3.99%. Intuitive Surgical has a consensus price target of $719.6471, indicating a potential downside of 8.87%. Given Edwards Lifesciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Edwards Lifesciences is more favorable than Intuitive Surgical.

Earnings & Valuation

This table compares Edwards Lifesciences and Intuitive Surgical's revenue, earnings per share (EPS) and valuation.

Intuitive Surgical has higher revenue and earnings than Edwards Lifesciences. Edwards Lifesciences is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Edwards Lifesciences and Intuitive Surgical's net margins, return on equity and return on assets.

Volatility & Risk

Edwards Lifesciences has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500. Comparatively, Intuitive Surgical has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500.

Summary

Intuitive Surgical beats Edwards Lifesciences on 9 of the 14 factors compared between the two stocks.

Edwards Lifesciences (NYSE:EW) and Stryker (NYSE:SYK) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, dividends, valuation and analyst recommendations.

Institutional and Insider Ownership

80.9% of Edwards Lifesciences shares are held by institutional investors. Comparatively, 71.5% of Stryker shares are held by institutional investors. 1.5% of Edwards Lifesciences shares are held by company insiders. Comparatively, 6.8% of Stryker shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and recommmendations for Edwards Lifesciences and Stryker, as reported by MarketBeat.

Edwards Lifesciences presently has a consensus price target of $90.8704, indicating a potential upside of 3.99%. Stryker has a consensus price target of $227.4783, indicating a potential downside of 5.78%. Given Edwards Lifesciences' higher possible upside, equities analysts clearly believe Edwards Lifesciences is more favorable than Stryker.

Earnings & Valuation

This table compares Edwards Lifesciences and Stryker's revenue, earnings per share (EPS) and valuation.

Stryker has higher revenue and earnings than Edwards Lifesciences. Stryker is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Edwards Lifesciences and Stryker's net margins, return on equity and return on assets.

Volatility & Risk

Edwards Lifesciences has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500. Comparatively, Stryker has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500.

Summary

Edwards Lifesciences beats Stryker on 8 of the 15 factors compared between the two stocks.

Edwards Lifesciences (NYSE:EW) and Becton, Dickinson and (NYSE:BDX) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, dividends, valuation and analyst recommendations.

Institutional and Insider Ownership

80.9% of Edwards Lifesciences shares are held by institutional investors. Comparatively, 83.2% of Becton, Dickinson and shares are held by institutional investors. 1.5% of Edwards Lifesciences shares are held by company insiders. Comparatively, 0.8% of Becton, Dickinson and shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and recommmendations for Edwards Lifesciences and Becton, Dickinson and, as reported by MarketBeat.

Edwards Lifesciences presently has a consensus price target of $90.8704, indicating a potential upside of 3.99%. Becton, Dickinson and has a consensus price target of $281.0769, indicating a potential upside of 7.40%. Given Becton, Dickinson and's stronger consensus rating and higher possible upside, analysts clearly believe Becton, Dickinson and is more favorable than Edwards Lifesciences.

Earnings & Valuation

This table compares Edwards Lifesciences and Becton, Dickinson and's revenue, earnings per share (EPS) and valuation.

Edwards Lifesciences has higher earnings, but lower revenue than Becton, Dickinson and. Becton, Dickinson and is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Edwards Lifesciences and Becton, Dickinson and's net margins, return on equity and return on assets.

Volatility & Risk

Edwards Lifesciences has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500. Comparatively, Becton, Dickinson and has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500.

Summary

Edwards Lifesciences beats Becton, Dickinson and on 8 of the 14 factors compared between the two stocks.

Edwards Lifesciences (NYSE:EW) and Boston Scientific (NYSE:BSX) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, dividends, valuation and analyst recommendations.

Institutional and Insider Ownership

80.9% of Edwards Lifesciences shares are held by institutional investors. Comparatively, 90.7% of Boston Scientific shares are held by institutional investors. 1.5% of Edwards Lifesciences shares are held by company insiders. Comparatively, 0.7% of Boston Scientific shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and recommmendations for Edwards Lifesciences and Boston Scientific, as reported by MarketBeat.

Edwards Lifesciences presently has a consensus price target of $90.8704, indicating a potential upside of 3.99%. Boston Scientific has a consensus price target of $43.0870, indicating a potential upside of 15.36%. Given Boston Scientific's stronger consensus rating and higher possible upside, analysts clearly believe Boston Scientific is more favorable than Edwards Lifesciences.

Earnings & Valuation

This table compares Edwards Lifesciences and Boston Scientific's revenue, earnings per share (EPS) and valuation.

Boston Scientific has higher revenue and earnings than Edwards Lifesciences. Boston Scientific is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Edwards Lifesciences and Boston Scientific's net margins, return on equity and return on assets.

Volatility & Risk

Edwards Lifesciences has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500. Comparatively, Boston Scientific has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500.

Summary

Boston Scientific beats Edwards Lifesciences on 8 of the 15 factors compared between the two stocks.